Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.11B 978M 908M 836M 1.57B 107B 1.6B 10.85B 4.23B 52.58B 4.18B 4.09B 182B P/E 2026 *
-7.38x
P/E 2027 * -6.68x
Enterprise Value 1B 882M 819M 754M 1.41B 96.9B 1.44B 9.78B 3.82B 47.42B 3.77B 3.69B 164B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 day+1.30%
1 week-2.24%
Current month+0.55%
1 month+21.95%
3 months+1.11%
6 months-9.63%
Current year+33.13%
1 week 10.37
Extreme 10.37
11.46
1 month 8.92
Extreme 8.92
12.06
Current year 7.23
Extreme 7.23
14.25
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
26.7
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 2018-05-06
Director of Finance/CFO 52 2019-08-31
Chief Tech/Sci/R&D Officer - 2025-08-17
Director TitleAgeSince
Chairman 68 2018-03-06
Director/Board Member 47 2018-05-06
Director/Board Member 62 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Sell

Founder

-300 0.0003%
2/24/26 Fiscal year

Chief Financial Officer

156,000 0.1602%
1/16/26 Sell

Founder

6,700 0.0069%
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%-2.24%-2.33%+26.92% 1.11B
+1.23%-3.08%+53.96%+87.98% 55.27B
+5.09%+6.18%+63.69%+62.06% 54.15B
+0.72%-2.19%+4.36%+409.54% 23.11B
+0.25%+0.08%-17.39%-15.22% 23.22B
+1.03%-0.76%+40.14%-3.59% 20.33B
-0.37%+0.42%+37.47%-31.61% 17.91B
+0.87%-2.80%+37.96%+600.00% 15.76B
-2.54%-12.88%+168.62%+289.45% 15B
+1.22%+0.18%+25.14%+182.63% 13.82B
Average +0.88%-0.68%+41.16%+160.82% 23.97B
Weighted average by Cap. +1.56%+1.17%+46.26%+137.88%

Financials

2026 *2027 *
Net sales - -
Net income -156M -137M -128M -117M -220M -15.09B -224M -1.52B -595M -7.38B -587M -574M -25.59B -190M -167M -155M -142M -267M -18.31B -272M -1.85B -722M -8.96B -712M -696M -31.06B
Net Debt -109M -96.07M -89.23M -82.11M -154M -10.56B -157M -1.07B -416M -5.17B -410M -401M -17.9B -231M -203M -189M -174M -326M -22.34B -332M -2.25B -880M -10.93B -868M -850M -37.89B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
104
Date Price Change Volume
26-07-23 US$10.89 +1.30% 2,168,815
26-07-22 US$10.75 -0.74% 1,037,311
26-07-21 US$10.83 +3.93% 1,309,676
26-07-20 US$10.42 -2.89% 821,940
26-07-17 US$10.73 0.00% 1,667,483
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
10.89USD
Average target price
20.69USD
Spread / Average Target
+90.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock